Skip to main content
. 2018 Mar 30;192(3):348–365. doi: 10.1111/cei.13112

Figure 3.

Figure 3

Summary of time‐points for immunogenicity assessment across adalimumab and infliximab studies by disease state. Immunogenicity testing occurred at several time‐points in most studies (number of specified time‐points reported/number of total reported time‐points).